Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 159 |
|
|||||
| News | - | ||||||
| Day High | 1.27 | Low High |
|||||
| Day Low | 1.27 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Protagenic Therapeutics Inc | PTIX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.14 | -9.93% | 1.27 | 09:23:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.27 | 1.27 | 1.27 | 1.41 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 4 | 159 | US$ 1.27 | US$ 202 | - | 0.6797 - 2.32 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 09:25:13 | 54 | US$ 1.29 | USD |
Protagenic Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.63M | 4.44M | - | 0 | -5M | -1.13 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Protagenic Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/14/2024 | 13:29 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 12/15/2023 | 14:50 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/29/2023 | 16:18 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/14/2023 | 15:02 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/02/2023 | 15:29 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 10/13/2023 | 11:48 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 8/14/2023 | 14:29 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PTIX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.30 | 1.80 | 1.27 | 1.55 | 21,935 | -0.03 | -2.31% |
| 1 Month | 1.71 | 1.80 | 1.1535 | 1.54 | 10,348 | -0.44 | -25.73% |
| 3 Months | 0.8622 | 1.87 | 0.8622 | 1.33 | 12,653 | 0.4078 | 47.30% |
| 6 Months | 0.7645 | 1.87 | 0.6797 | 1.16 | 9,214 | 0.5055 | 66.12% |
| 1 Year | 1.82 | 2.32 | 0.6797 | 1.29 | 9,037 | -0.55 | -30.22% |
| 3 Years | 9.32 | 19.56 | 0.6797 | 11.30 | 438,259 | -8.05 | -86.37% |
| 5 Years | 11.00 | 19.56 | 0.6797 | 11.27 | 442,496 | -9.73 | -88.45% |
Protagenic Therapeutics Description
| Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. |
